BMS will co-develop and co-commercialize BioNTech’s bispecific antibody BNT327 for solid tumors in a deal worth up to $11.1B ...

The trial is set to take place at sites across several European countries including Spain, the UK and Belgium.

Researchers at the Ragon Institute have made a significant discovery about how antibodies can directly enhance the body's ...

The results feed into an effort to identify to monoclonal antibody combinations that would prevent and possibly treat HIV ...

Results from three trials continue to demonstrate the potential of DATROWAY® (datopotamab deruxtecan) in combination with ...

A new study has shown that person-to-person variation in antibody immunity plays a key role in shaping which influenza (flu) ...

Two-Part Dose Escalation and Expansion Trial Will Evaluate Efficacy and Safety of BYON4228 Alone and in Combination with Pembrolizumab NIJMEGEN, The ...

Agenus, which has been going through a reorganization after the FDA put the brakes on the biotech's regulatory plan for its ...

Radionuclide therapy with the radioactive element terbium could effectively combat lymphoma. This is demonstrated by ...

US pharma major Bristol Myers Squibb (NYSE: BMY) has entered into an agreement for the global co-development and ...

New research suggests that an antibody-drug conjugate may offer practice-changing, patient-friendly treatment of blastic ...

The strong immune response was confirmed in CHIKV-naïve children with a 96.5% seroresponse rate (full dose) at Day 180. VLA1553 was well tolerated in children aged one to eleven years regardless of ...